Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Suspended 1Completed 1

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 3Tumor-Agnostic 2Sarcoma 2Other hematologic neoplasm 2Gastrointestinal 2Breast 2Other solid neoplasm 1Lymphoid 1Head & Neck 1Genitourinary 1CNS 1

Conditions

Neoplasm Metastasis 2Breast Neoplasms 2Pain 1Humoral Hypercalcemia Of Malignancy 1

Interventions

Trastuzumab 242Paclitaxel 223Fulvestrant 196Capecitabine 182Docetaxel 164Letrozole 142pembrolizumab 115Carboplatin 100exemestane 98Gemcitabine 98Cyclophosphamide 92palbociclib 86Anastrozole 83pertuzumab 78Lapatinib 73Bevacizumab 71ribociclib 68130-nm albumin-bound paclitaxel 66abemaciclib 59eribulin 58Doxorubicin 55Vinorelbine 51Injections 47Ado-Trastuzumab Emtansine 47Tamoxifen 45Everolimus 44Albumin-Bound Paclitaxel 44atezolizumab 35trastuzumab deruxtecan 34Nivolumab 34

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Antibodies, Monoclonal × Breast × Clear all
NCT04120246 2024-07-10

Alpha-TEA and Trastuzumab for the Treatment of Refractory HER2+ Metastatic Breast Cancer

Veana Therapeutics

Phase 1 Suspended
24 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis

NCT00060138 2013-05-15

Monoclonal Antibody Compared With Zoledronate in Treating Women With Breast Cancer and Bone Metastases

Chugai Pharmaceutical

Phase 1/2 Completed
Breast

Humoral Hypercalcemia Of Malignancy, Breast Neoplasms, Neoplasm Metastasis, Pain

Data powered by HemOnc (CC BY 4.0) Colophon âš¡